- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| BIOSERGEN Aktie jetzt für 0€ handeln | |||||
| 01.12.25 | XFRA NEW INSTRUMENTS AVAILABLE ON 01.12.2025 | 403 | Xetra Newsboard | The following instruments on XETRA do have their first trading 01.12.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 01.12.2025
Aktien
1 IT0005678104 Kaleon S.p.A.
2 IM00BYYPQX37... ► Artikel lesen | |
| 28.11.25 | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 28.11.2025 | 1.068 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 28.11.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 28.11.2025ISIN NameCA38940L2057 GRAYCLIFF... ► Artikel lesen | |
| 28.11.25 | XFRA ISIN CHANGE | 411 | Xetra Newsboard | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenCA60283T2074 Mineral Hill Industries Ltd. 28.11.2025 CA38077F1045 Gold Strategy Inc. 01.12.2025 Tausch 1:1US60855D3098 Moleculin... ► Artikel lesen | |
| 28.11.25 | XFRA CAPITAL ADJUSTMENT INFORMATION - 28.11.2025 | 345 | Xetra Newsboard | Das Instrument 8N1 SE0016013460 BIOSERGEN AB EQUITY wird cum Kapitalmassnahme gehandelt am 28.11.2025 und ex Kapitalmassnahme am 01.12.2025 The instrument 8N1 SE0016013460 BIOSERGEN AB EQUITY is traded... ► Artikel lesen | |
| 27.11.25 | Reverse split and Change of ISIN for Biosergen AB | 239 | GlobeNewswire | The company will carry out a reverse stock split in a ratio of 1:100. The share will be traded under new ISIN code with effect from Dec 1, 2025. The order book will not change.
Short... ► Artikel lesen | |
| 20.11.25 | Biosergen AB: Determination of Record Date for Reverse Share Split in Biosergen | 167 | GlobeNewswire (Europe) | STOCKHOLM, November 20, 2025. At the Annual General Meeting of Biosergen AB ("Biosergen" or the "Company") on June 11, 2025, a resolution was passed on a reverse split of shares, whereby one hundred... ► Artikel lesen | |
| 19.11.25 | Biosergen AB: Biosergen publishes interim report for the third quarter 2025 | 162 | GlobeNewswire (Europe) | November 19, 2024: Biosergen AB ("Biosergen" or the "Company") hereby publishes the interim report for the third quarter 2025. The interim report is available as an attached document and on the company... ► Artikel lesen | |
| 28.10.25 | BIOSERGEN AB: Biosergen's Nomination Committee appointed | 1 | Cision News | ||
| 20.08.25 | Biosergen AB: Biosergen publishes its interim report for the second quarter 2025 | 176 | GlobeNewswire (Europe) | Wednesday August 20, 2024: Biosergen AB ("Biosergen" or the "Company") hereby publishes the interim report for the second quarter 2025. The interim report is available as an attached document and on... ► Artikel lesen | |
| 24.07.25 | Biosergen AB: Biosergen Appoints Mark Beveridge as Chief Financial Officer | 208 | GlobeNewswire (Europe) | Stockholm, Sweden - July 24, 2025 - Biosergen AB ("Biosergen" or the "Company"), a clinical-stage biotechnology company developing therapies for life-threatening fungal infections, today announces the... ► Artikel lesen | |
| 21.05.25 | Biosergen AB: Biosergen publishes interim report for the first quarter 2025 | 193 | GlobeNewswire (Europe) | May 21, 2025: Biosergen AB ("Biosergen" or the "Company") hereby publishes the interim report for first quarter 2025. The interim report is available as an attached document and on the company website... ► Artikel lesen |
11 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 319,57 | +4,56 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| QIAGEN | 43,170 | -0,70 % | Ionos, Kontron, Lanxess, Qiagen, Redcare Pharmacy, Siltronic, TeamViewer: Neue Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,90 | +0,11 % | Avidity Biosciences, Inc. - 8-K, Current Report | ||
| TARSUS PHARMACEUTICALS | 64,62 | +4,24 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements | Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,990 | +8,23 % | H.C. Wainwright reiterates Buy rating on Summit Therapeutics stock | ||
| ERASCA | 12,290 | +3,45 % | Erasca, Inc.: Erasca Announces Pricing of Upsized Public Offering of Common Stock | SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for... ► Artikel lesen | |
| AGOMAB THERAPEUTICS | 14,650 | 0,00 % | AgomAb Therapeutics N.V.: Agomab Announces Pricing of Initial Public Offering | ANTWERP, Belgium, February 5, 2026 (GLOBE NEWSWIRE) - Agomab Therapeutics NV (Nasdaq: AGMB) ("Agomab"), a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,960 | +11,24 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 62,19 | +0,10 % | Jefferies lowers Apogee Therapeutics stock price target on OX40 concerns | ||
| IMMUNOVANT | 27,040 | +12,39 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025 | IMVT-1402 potentially registrational trial in difficult-to-treat rheumatoid arthritis (D2T RA) fully enrolled, with topline data expected in the second half of calendar year 2026; topline data from... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 74,96 | +2,39 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity | SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 29,770 | +5,53 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics' Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) "Research of the Year" Roundup | - Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impactful... ► Artikel lesen | |
| SPYGLASS PHARMA | 26,400 | 0,00 % | SpyGlass Pharma Prices IPO At $16 Per Share | WASHINGTON (dpa-AFX) - SpyGlass Pharma, Inc. (SGP), a late-stage biopharmaceutical company, announced the pricing of its initial public offering of 9.38 million shares at $16 per share.The company... ► Artikel lesen | |
| LIMINATUS PHARMA | 1,840 | -10,24 % | Liminatus Pharma, Inc. - 8-K, Current Report | ||
| DAY ONE BIOPHARMACEUTICALS | 11,410 | +8,87 % | Day One Biopharmaceuticals, Inc.: Day One Announces Preliminary 2025 OJEMDA Net Product Revenue And Provides 2026 Net Product Revenue Guidance | Preliminary 2025 net product revenue of $155.4 million, representing 172% year-over-year growth; OJEMDA 2026 U.S. net product revenue projected to be $225 - $250 million Company to present on corporate... ► Artikel lesen |
BIOSERGEN AB gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 3,900 Euro und damit -0,51 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOSERGEN AB finden Sie auf Wallstreet Online.